Cancer Drug Assistance Scheme 2.0 Expands to 60 Slots with Cross-Border Care Support
SingTao · 1 SOURCESabout 1 hour ago2 MIN
Summary
The Cancer Information Community Charity Fund unveiled the "Hong Kong Patients Cancer Drug Assistance Scheme 2.0" at a press conference on September 9, 2026, significantly expanding support for local cancer patients facing prohibitive medication costs. The programme, supported by the Kerry Group Kuok Foundation and Chow Tai Fook Medical Fund, increases its quota from 50 to 60 beneficiaries while extending cross-border medical services to four designated Shenzhen hospitals. The initiative addresses the urgent needs of late-stage patients, with 96.4 percent of pilot scheme recipients being Stage 3 or 4 patients who require expensive targeted drug therapies .
Key Points
- The pilot programme successfully assisted 55 patients, with 96.4 percent (53 individuals) being late-stage patients in Stages 3-4, highlighting the critical timing of the subsidies
- Non-social security assistance patients accounted for 76.4 percent (42 individuals), demonstrating that middle-income "sandwich class" families face the greatest unmet need for drug cost support
- Lung cancer patients represented the largest beneficiary group at 74.5 percent (41 people), followed by breast cancer at 10.9 percent (6 people) and colorectal cancer at 5.5 percent (3 people)
- The quota has been increased to 60 beneficiaries with no cap on the number of targeted cancer drugs covered within the funding limit, and designated Shenzhen medical institutions expanded from 2 to 4 facilities
- The scheme provides comprehensive support including drug subsidies, cross-border escort services, and medical information counselling to help patients navigate complex treatment procedures
Why It Matters
For Hong Kong's cancer patients and their families, this enhanced programme represents a crucial lifeline as many next-generation targeted therapies remain financially out of reach within the public healthcare system. The expansion of cross-border services aligns with the Elderly Health Care Voucher Greater Bay Area Pilot Scheme, potentially setting a precedent for broader integration of Hong Kong's healthcare system with mainland medical resources . While the fund emphasises that cross-border medication purchasing should serve only as a transitional bridge, it underscores the urgent need for government intervention to make essential cancer drugs more affordable and accessible within Hong Kong itself .
For Hong Kong's cancer patients and their families, this enhanced programme represents a crucial lifeline as many next-generation targeted therapies remain financially out of reach within the public healthcare system. The expansion of cross-border services aligns with the Elderly Health Care Voucher Greater Bay Area Pilot Scheme, potentially setting a precedent for broader integration of Hong Kong's healthcare system with mainland medical resources . While the fund emphasises that cross-border medication purchasing should serve only as a transitional bridge, it underscores the urgent need for government intervention to make essential cancer drugs more affordable and accessible within Hong Kong itself .